Description
An orally active, selective inhibitor of Cdk4 (IC50 = 11 nM) and Cdk6 (IC50 = 16 nM) with antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest; used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism
Formal name: 6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one, monohydrochloride
Synonyms: Palbociclib
Molecular weight: 484
CAS: 827022-32-2
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Cycle|G1||Research Area|Cancer|Cell Signaling||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes